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Objective: To evaluate the accuracy of the risk of malignancy index (RMI) which combines serum CA-125
levels, ultrasound score, and menopausal state, in discriminating between benign and malignant adnexal
masses in the Welsh population.
Materials and methods: Two hundred and forty-seven women with pelvic masses discussed consecu-
tively at the South West Wales Gynaecological Oncology multidisciplinary meeting between January
2010 and June 2011 were included in this retrospective study. The main outcomes were surgical and
pathological ﬁndings.
Results: The sensitivity and speciﬁcity of CA-125 at 35kU/L were 76% and 67%, respectively. CA-125 was
found to be a relevant predictor of malignancy but the area under the receiver operating characteristic
curve for each of the risk of malignancy indices was greater than the area for the CA-125 serum levels
alone. Each of the RMIs has a different optimal threshold, however using a threshold of 200, RMI 1 had a
sensitivity of 66% and a speciﬁcity of 91%; RMI 2 had a sensitivity of 74% and a speciﬁcity of 79%; and RMI
3 had a sensitivity of 68% and a speciﬁcity of 85%.
Conclusion: This is the ﬁrst study in Wales to evaluate the RMI in triaging women with pelvic masses.
Overall, RMI 1 and RMI 2 are better malignancy predictors than RMI 3. It would be recommended that
RMI 1 and RMI 2 be compared in a head-to-head prospective study, although we suspect that RMI 1 is
likely to be the overall best malignancy predictor.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ovarian cancer is a common gynaecological malignancy with a
high mortality. In 2008, the disease was diagnosed in approxi-
mately 225,000 women worldwide, accounting for approximately
4% of all cancers diagnosed in women with corresponding 140,000
deaths [1]. In Wales, 373 women received a diagnosis of ovarian
cancer in 2007, increasing by more than 5% in 2008 to 392 [2].
Ovarian cancer is more common in older women, with the highest
incidence in those aged 75e79 years. [2]. Despite of advances in
chemotherapy, ovarian cancer remains a lethal disease. This is
because the disease is usually diagnosed at an advanced stage
becausemost of the symptoms are nonspeciﬁc; hence, the difﬁcultyion, Cardiff University School
rk, Cardiff CF14 4XW, United
dulrahman).
bstetrics & Gynecology. Publishedin diagnosis at early stages. More than 60% of women presenting
with ovarian cancer have Stage III or IV cancer when metastasis is
already present, with 5-year relative survival of just 27% [3]. Only
15% of womenpresent when themalignancy is still localized, with a
5-year relative survival of 92% [3].
Ovarian tumors present with a variety of symptoms, including
abdominal pain, abdominal or adnexal mass, bloating, urinary ur-
gency, and abnormal vaginal bleeding. Such clinical presentation
could be caused by a number of different benign and malignant
conditions.Asa result, it usuallyposesa challenge to thegynecologist
to distinguish betweenbenign andmalignant tumors. Consequently,
there has been vigorous research into ovarian cancer screening
methods and diagnostic tools. In 1990, Jacobs et al [4] developed the
risk of malignancy index (RMI) after assessing how age, ultrasound
score, menopausal status, clinical impression score, and serum CA-
125 level could best distinguish between patients with benign and
malignant pelvic masses. They noted that each criterion used alone
provided statistically signiﬁcantdiscrimination,with themostusefulby Elsevier Taiwan LLC. All rights reserved.
Table 1
The three versions of RMI compared in this study.
M U
RMI 1 [4] 1 if premenopausal
3 if postmenopausal
0 if no abnormality
1 if one abnormality
3 if  2 abnormalities
RMI 2 [5] 1 if premenopausal
4 if postmenopausal
1 if  1 abnormality
4 if  2 abnormalities
RMI 3 [6] 1 if premenopausal
3 if postmenopausal
1 if  1 abnormality
3 if  2 abnormalities
M ¼ menopausal status; RMI ¼ risk of malignancy index; U ¼ ultrasound score.
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81%, speciﬁcity 75%) and an ultrasound score of 2 (sensitivity 71%,
speciﬁcity 83%) [4]. Jacobs et al therefore proposed that the combi-
nation of three criteria in an RMI is an effective tool to distinguish
between cancer and benign lesions and is calculated using the
product of the serum CA-125 level (U/mL), the ultrasound result
(expressed as a score of 0, 1, or 3) and the menopausal status (1 if
premenopausal and 3 if postmenopausal). By using an RMI cutoff
level of 200, the sensitivitywas 85%whereas the speciﬁcitywas 97%,
and patientswith an RMI score ofmore than 200 had, on average, 42
times the background risk of cancer compared to 0.15 times the
background risk in thosewith a lower score [4]. Tingulstad et al [5,6]
developed modiﬁed RMI in 1996 (RMI 2) and 1999 (RMI 3), with
differences mainly in scorings of ultrasound ﬁndings and meno-
pausal status.
Although the Guideline Development Group of the National
Institute for Health and Clinical Excellence (NICE) suggested that
RMI 1was themost useful index at identifying womenwith ovarian
cancer compared to other malignancy indices in secondary care, it
noted that current evidence did not indicate the optimum cutoff
score to use for guiding management [7]. It therefore recom-
mended that further research should be undertaken to determine
the optimum threshold for RMI 1 that should be applied in sec-
ondary care to guide the management of women with suspected
ovarian malignancy [7].
The purpose of this study is to evaluate the accuracy of the RMI,
which combines serum CA-125 levels, ultrasound score, and
menopausal state, in distinguishing between benign andmalignant
pelvic masses in the Welsh population. Although studies have
validated the RMI in various populations [8e15], none has been
done in Wales. This study is also aimed at determining the opti-
mum threshold for the three RMIs. The long-term aim is to have a
uniﬁed risk scoring system across Wales.
Materials and methods
The Abertawe Bro Morgannwg University Health Board is one of
the largest health boards in Wales serving a population of
approximately 600,000 covering the areas of Bridgend, Neath Port
Talbot, and Swansea in South West Wales, United Kingdom. The
Gynaecology Multidisciplinary Team (MDT) is based at the
Singleton Hospital in Swansea, which is a 550-bed district general
hospital. In addition to patients from Singleton Hospital, the Gy-
naecology MDT also discusses patients referred from seven other
National Health Service (NHS) hospitals and many private clinics.
The Trust's database was used to identify womenwho had been
referred to the gynecological oncology unit for management of
pelvic mass and were discussed at the Multidisciplinary Meeting
(MDM) over an 18-month period between January 2010 and June
2011. A total of 328 patients were identiﬁed in the database. Fifteen
of the records were either incomplete or unavailable for review.
Fifty-three of the remaining charts did not have an ultrasound
examination and CA-125 was not recorded in six of the charts.
Seven of the patients did not have both ultrasound examination
and CA-125 recorded. Hence, a total of 247 patients were included
in this retrospective review.
Three versions of RMI were compared, each incorporated serum
CA-125 level, menopausal status, and ultrasound ﬁndings (Table 1).
To calculate the RMI, the formula serum CA-125 x M x U is used.
Serum CA-125 is the assayed level of the tumor marker expressed
in kU/L, M refers to the menopausal status of the patient, and U is
the ultrasound score.
In Singleton Hospital, CA-125 is considered normal if it
is < 35 kU/L and it is commonly measured in women presenting
with adnexal masses.Ultrasound score is computed based on the presence or absence
of ﬁve features e multiloculated cyst, evidence of solid areas,
bilateral lesions, presence of ascites, and evidence of metastases. In
RMI 1, U ¼ 0 if none of these features is present, 1 if one feature is
present, and 3 if two or more features are present. For RMI 2, U ¼ 1
if none or one feature is present and 4 if two or more features are
present. In RMI 3, U¼ 1 if none or one feature is present and 3 if two
or more features are present.
Surgical specimens are usually sent for histology and the results
of patients included in this study were documented. In some cases
where the lesion was considered benign from imaging review,
resulting in no surgical intervention, the diagnosis was assumed to
be correct (for example, ovarian cyst not otherwise speciﬁed).
The data were analyzed using PASW Statistics for Windows,
Version 18.0 (SPSS Inc., Chicago). A p-value of < 0.05 was consid-
ered statistically signiﬁcant using Pearson Chi-square test. A
receiver operating characteristic (ROC) curvewas produced to show
the relation between sensitivity and speciﬁcity of the RMI in dis-
tinguishing between benign and malignant masses. The closer the
ROC curve is to the upper left corner, the higher the overall accuracy
of the test [16].Results
Two hundred forty-seven women with adnexal masses were
included in this retrospective study with a mean age of 58.09 years
(range 19e95 years). One hundred sixty of the women had benign
masses, whereas 87 women had malignant masses, giving a ratio of
2:1. Eighty patients were premenopausal, of whom 59 had benign
masses and 21 had malignant masses. The number of post-
menopausal women was 167 and of these, 101 had benign lesions
whereas 66 had malignant neoplasm. The average age of women
with benign lesions was 56.96 ± 17.991 years [95% conﬁdence in-
terval (CI), 54.15e59.77] and the average age for women with
malignant masses was 60.16 ± 15.6 years (95% CI, 56.84e63.49).
Postmenopausal women have a higher incidence of both benign
and malignant lesions (p ¼ 0.041). The 51e60 age group had the
highest incidence of ovarian malignancy (n ¼ 23).
The presence of ascites on ultrasound examination was signiﬁ-
cantly associated with a higher possibility of malignant adnexal
mass (p < 0.001). There was no association between parity and
pelvic mass (p ¼ 0.748).
Of the 87 women in whom malignant masses were diagnosed,
the International Federation of Gynecology and Obstetrics stage
was not recorded in 13 patients. Most of the patients presented at
Stage I (n ¼ 41), four presented at Stage II, 17 presented at Stage III,
and 12 presented at Stage 4 (Fig. 1). Most of the patients had Stage
Ia malignant disease (n ¼ 25), whereas 13 patients presented at
Stage IIIc; 15 patients had Stage Ic malignant disease, whereas four
patients presented with Stage IIb disease. Only one patient pre-
sented at Stage Ib and three presented at Stage IIIb. None presented
at Stage IIa, IIc, or IIIa. In one patient, it was concluded that the
Fig. 1. Distribution by stage of ovarian malignancy.
Table 3
Statistical differences between benign and malignant groups on ultrasound
ﬁndings.
Ultrasound
score
Benign,
n (%)
Malignant,
n (%)
p
RMI 1 0 86 (53.7) 4 (4.6) < 0.001
1 44 (27.5) 29 (33.3)
3 30 (18.8) 54 (62.1)
RMI 2 1 130 (81.3) 33 (37.9) < 0.001
4 30 (18.7) 54 (62.1)
RMI 3 1 130 (81.3) 33 (37.9) < 0.001
3 30 (18.7) 54 (62.1)
RMI ¼ risk of malignancy index.
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Most of the benign ovarian lesions were unspeciﬁed ovarian
cysts (n ¼ 106). Other benign lesions that were diagnosed include
dermoid cyst (n ¼ 10), serous cystadenoma (n ¼ 8) and mature
teratoma (n ¼ 7). The most common malignant histological di-
agnoses were serous cystadenocarcinoma and papillary serous
cystadenocarcinoma (Table 2).
Statistically signiﬁcant differences were recorded between the
benign andmalignant groups in the ultrasound score variable. Most
of the women with two or more ultrasound abnormalities had
malignant pathology (Table 3).
The mean serum CA-125 level in the benign and malignant
groups was 50.86 kU/L and 654.34 kU/L, respectively. The sensi-
tivity and speciﬁcity of CA-125 at 35 kU/L was 76% and 67%,
respectively (Table 4). CA-125 was found to be a relevant predictor
of malignancy with an area under the ROC curve of 0.81. However,
the area under the ROC curve for each of the risk of malignancy
indices was greater than the area for the CA-125 serum levels. The
comparisons between the sensitivity and speciﬁcity of the RMI
scores and the individual elements of the scoreeCA-125, meno-
pausal status, and ultrasound scoreealso showed that the perfor-
mance of the RMI was better than the individual elements.
The average RMI 1 for benign masses was 61.30 and 4387.02 for
malignant masses (p < 0.001). For RMI 2, the mean for benignTable 2
Histological diagnoses of the 87 women with malignant ovarian masses.
Malignant histology n (%)
Serous cystadenocarcinoma 17 (19.54)
Papillary serous cystadenocarcinoma 16 (18.39)
Mucinous cystadenocarcinoma 10 (11.49)
Serous cystadenoma 9 (10.34)
Mucinous cystadenoma 9 (10.34)
Endometrioid tumor 6 (6.90)
Clear cell tumor 5 (5.75)
Mixed tumor 3 (3.45)
Cystadenocarcinoma 3 (3.45)
Metastatic 3 (3.45)
Immature teratoma 1 (1.15)
Granulosa cell tumor 1 (1.15)
Neuroendocrine carcinoma 1 (1.15)
Carcinosarcoma 1 (1.15)
Not speciﬁed 2 (2.30)
Total 87 (100)masses was 152.80 and 7581.21 for malignant masses (p ¼ 0.004).
For RMI 3, the mean for benign and malignant masses were 115.44
and 4406.41, respectively (p ¼ 0.001). RMI 1 had the greatest area
under the ROC curve of 0.89 [standard error (SE) 0.022, asymptotic
95% CI 0.850e0.936]. The area under the ROC curve for RMI 2 was
0.844 (SE 0.028 asymptotic 95% CI 0.789e0.899) and for RMI 3 was
0.842 (SE 0.028 asymptotic 95% CI 0.787e0.897) (Fig. 2). Using a
threshold of 200, RMI 1 had a sensitivity of 66% and a speciﬁcity of
91%; RMI 2 had a sensitivity of 74% and a speciﬁcity of 79%; and RMI
3 had a sensitivity of 68% and a speciﬁcity of 85% (Table 5). Using a
RMI cutoff level of 250, the sensitivity of RMI 1 dropped to 60%
while the speciﬁcity increased to 94%. The sensitivity of RMI 2 also
dropped to 71% and the speciﬁcity was 84%. At a threshold of 250,
RMI 3 also recorded a drop in sensitivity to 61% and the speciﬁcity
increased to 90% (Table 5). A lower threshold of 120 for RMI 1,
however, revealed a sensitivity of 74% and speciﬁcity of 84%.Discussion
Main ﬁndings
The aim of this study was to determine if the three versions of
RMI, which combines serum CA-125 levels, ultrasound ﬁndings,
and menopausal state, can distinguish between benign and ma-
lignant adnexal masses. The results of this study will facilitate more
appropriate referrals to the specialized gynecological oncology
centers across Wales and help in determining the necessity of
surgery, resulting in appropriate care for women with gynecolog-
ical malignancies and optimization of healthcare resources.
Many of the women in this study who had malignant pelvic
masses were at Stage 1. The lower numbers in Stages 3 and 4 could
be because most of the women at these stages would have pre-
sented with obvious symptoms of malignancy. Therefore, they
would have had a CT rather than an ultrasound, which would make
them ineligible for inclusion into this study.
Although the area under the ROC curve for each of the risk of
malignancy indices was greater than the area for the CA-125 serum
levels, CA-125 was still found to be a relevant predictor of malig-
nancy. At 50 kU/L, 78% of malignant masses were detected. It wouldTable 4
Sensitivity, speciﬁcity, positive predictive value, and negative predictive value of CA-
125 for predicting malignancy.
Variables (kU/L) Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
35 76 67 56 84
50 66 78 62 81
150 48 95 84 77
200 39 95 81 74
300 37 98 91 74
NPV ¼ negative predictive value; PPV ¼ positive predictive value.
Fig. 2. Receiver operating characteristic (ROC) curves for CA-125 levels, RMI 1, RMI 2,
and RMI 3 in the discrimination between benign and malignant adnexal masses.
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women with CA-125 levels above 50 kU/L to the secondary health
centers.
This study demonstrates the ability of RMI to correctly identify
benign and malignant adnexal masses. It shows the high speciﬁcity
of all the three risk of malignancy indices at an optimal cutoff of
200. The speciﬁcities for RMI 1, RMI 2, and RMI 3were 91%, 79%, and
85% respectively, which is similar to previous studies [17,18]. A high
speciﬁcity is important because it reduces the number of surgical
procedures performed for benign cases in tertiary gynecological
oncology centers, therefore optimizing resources for patients with
malignant pelvic masses. Using a cutoff of 200, the preoperative
RMI had a sensitivity of 66%, 74%, and 68% for RMI 1, RMI 2, and RMI
3, respectively.
The RMI 3 is a modiﬁed version of the RMI 1, which was pro-
posed by Tingulstad et al [6]. In their study, they observed that
sensitivity and speciﬁcity to malignancy were 71% and 92%
respectivelywhen a cutoff of 200was used [6]. In this study, when a
cutoff of 200was used for RMI 3, the sensitivity and speciﬁcity were
68% and 85%, respectively, which were comparable to Tingulstad
et al's results.
Some studies have found that RMI 2 is more reliable in preop-
erative evaluation of womenwith pelvic masses [5,19,20]. However,
in this study, the performance of the malignancy indices varied
depending on the threshold used.
The optimal threshold for each of the three RMIs varied,
although many studies used a cutoff of 200 for the three RMIsTable 5
Sensitivity, speciﬁcity, positive predictive value, and negative predictive value for predic
RMI cutoff Sensitivity (%) Speciﬁcity (%)
RMI 1 RMI 2 RMI 3 RMI 1 RMI 2 RM
25 94 98 98 59 14 17
150 71 78 74 88 71 80
200 66 74 68 91 79 85
250 60 71 61 94 84 90
300 59 68 60 95 87 93
NPV = negative predictive value; PPV = positive predictive value; RMI = risk of malignan[5,8,19,21]. For RMI 1, the optimal threshold is 120with a sensitivity
of 74% and speciﬁcity of 84%. For RMI 2, it was 200with a sensitivity
and speciﬁcity of 74% and 79%, respectively. The balance was ach-
ieved at a threshold of 150 for RMI 3 with a sensitivity of 74% and
speciﬁcity of 80%. The lower cutoff for RMI 1 is probably because an
ultrasound score of 0 is assigned when none of the ultrasound
features are present, resulting in an RMI of 0 regardless of the
serum CA-125 level and menopausal status. However, ultrasound
results are heavily operator dependent and a sinister mass may be
inadvertently reported as normal by an operator, resulting in a low
RMI evenwhen the CA-125, which is an important parameter of the
RMI, is abnormal.
Had a cutoff of 200 been used for the three RMIs, six malignant
cases identiﬁed by RMI 2 would have been missed using RMI 1. RMI
3 would have missed ﬁve malignant cases identiﬁed by RMI 2. The
ﬁve malignant cases missed by both RMI 1 and 3 were two
borderline mucinous cystadenoma, one high-grade papillary se-
rous cystadenocarcinoma, one clear cell tumor, and one borderline
serous cystadenoma. In addition, RMI 1 also missed one poorly
differentiated serous cystadenocarcinoma. It is not surprising that
some of the borderline tumors were missed because they tend to
have lower RMI scores compared to invasive malignancies, hence
they are less detectable. This is because borderline tumors exhibit
different characteristics biochemically and morphologically from
invasive malignancies and are therefore unlikely to be detected
using tests designed primarily to detect invasive malignant dis-
eases [22].
The gynecological oncology MDT in Singleton Hospital currently
uses RMI 1 based on NICE's recommendation. The MDT considers
pelvic masses with an RMI 1 score < 25 as low risk, which should be
managed locally, 25e250 as intermediate risk, which would be
discussed at theMDTandmanaged locally if appropriate, and > 250
as high risk, which would require further investigation and im-
mediate referral to a cancer center. Based on this study, a threshold
of 250 has a sensitivity and speciﬁcity of 60% and 94%, respectively,
for RMI 1. While noting that current evidence did not indicate the
optimum cutoff to use for guiding management, NICE recommends
a cutoff of 250 because it was thought that this would ensure access
to specialist centers without overburdening them with benign
disease and the associated additional costs [7]. This study shows
that RMI 1 threshold of 250 has a high speciﬁcity indeed, although
the sensitivity has been affected relative to the speciﬁcity. However,
using a cutoff of 200, the sensitivity increased to 66% without any
major loss of speciﬁcity (91%).
Strengths
This is the ﬁrst study in Wales to validate the use of the risk of
malignancy indices in the preoperative evaluation of women with
pelvic masses in the Welsh population. With almost one-ﬁfth of
Wales' population in the region where this study was conducted,
the local authority area's age and sex proﬁle is very similar to that of
Wales as a whole [23]. This study also has a large sample sizeting malignancy at different cutoff levels of RMI 1, RMI 2, and RMI 3.
PPV (%) NPV (%)
I 3 RMI 1 RMI 2 RMI 3 RMI 1 RMI 2 RMI 3
55 38 39 95 93 94
76 59 67 85 86 85
80 66 71 83 85 83
85 71 77 81 84 81
87 74 82 81 83 81
cy index.
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making the ﬁndings of this study more reliable.Limitations
A major limitation of this study is the retrospective design. A
future prospective study is likely to have fewer potential sources of
bias and confounding. Furthermore, because our center is a major
referral center for SouthWest Wales, it is likely that the percentage
of malignant lesions in this study is higher than in peripheral
hospitals where a larger proportion of women would present with
benign pelvic masses. In addition, we do not know the outcome of
some of the patients considered to be low risk that we sent back to
the peripheral hospitals for management. Such information could
have affected our results.Interpretation
The RMI is a simple scoring system that is easily applicable to
daily clinical practice. It is important that every center in Wales
adopts only one version of the RMIs in its evaluation of cases with
its corresponding optimal cutoff so as to ensure consistency and to
avoid confusion. It would also be suggested that each center eval-
uates the interobserver and intraobserver variations in ultrasound
examinations of pelvic masses so as to ensure reproducibility and
accuracy of consequent ultrasound scorings. The possibility of
scoring from computed tomography scans should also be evaluated
because many women with suspicious adnexal masses currently
are evaluated with computed tomography in the absence of
ultrasonography.Conclusion
Practical recommendations
This is the ﬁrst study in Wales to evaluate the accuracy of RMI 1,
RMI 2, and RMI 3 in discriminating between benign and malignant
pelvic masses in the Welsh population. RMI is a simple and cheap
scoring system that should be adopted across Wales in referring
patients to the specialist cancer centers, especially because of our
wide geographical area and low population density. According to
the ROC curve, RMI 1 and RMI 2 performed better than RMI 3 in
triaging women with pelvic masses. RMI 2 performed better than
RMI 1 and RMI 3 at the cutoff of 200, which is comparable to
published studies, but overall RMI 1 appears to be the best
predictor.
It should be noted that RMI is only a guide; therefore, patients
with a family history of ovarian and/or breast cancer and thosewith
past medical history of breast and reproductive tract malignancy
should be further evaluated even when their RMI score is low.Research recommendations
At a cutoff of 200, RMI 2 was the most sensitive, although less
speciﬁc than RMI 1 and RMI 3. Overall, RMI 1 and RMI 2 are better
malignancy predictors than RMI 3. It is therefore suggested that
both RMI 1 and RMI 2 be compared in a head-to-head prospective
study, althoughwe suspect that RMI 1 is likely to be the overall best
malignancy predictor.Conﬂicts of interest
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